Overview

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia

Status:
NOT_YET_RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Huilun Pharmaceutical Co., Ltd.

Treatments:

Control Groups
silodosin